Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 15
1976 19
1977 21
1978 31
1979 36
1980 38
1981 42
1982 45
1983 49
1984 37
1985 36
1986 44
1987 58
1988 48
1989 61
1990 66
1991 66
1992 85
1993 72
1994 77
1995 102
1996 97
1997 105
1998 111
1999 108
2000 134
2001 171
2002 167
2003 232
2004 235
2005 266
2006 256
2007 233
2008 280
2009 286
2010 307
2011 375
2012 367
2013 383
2014 449
2015 461
2016 355
2017 269
2018 441
2019 464
2020 512
2021 574
2022 557
2023 473
2024 137

Text availability

Article attribute

Article type

Publication date

Search Results

8,859 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management.
McCarthy C, Gupta N, Johnson SR, Yu JJ, McCormack FX. McCarthy C, et al. Lancet Respir Med. 2021 Nov;9(11):1313-1327. doi: 10.1016/S2213-2600(21)00228-9. Epub 2021 Aug 27. Lancet Respir Med. 2021. PMID: 34461049 Review.
Lymphangioleiomyomatosis (LAM) is a slowly progressive, low-grade, metastasising neoplasm of women, characterised by infiltration of the lung parenchyma with abnormal smooth muscle-like cells, resulting in cystic lung destruction. ...Further research is needed to better un …
Lymphangioleiomyomatosis (LAM) is a slowly progressive, low-grade, metastasising neoplasm of women, characterised by infiltration of …
Lymphangioleiomyomatosis: a metastatic lung disease.
Kundu N, Holz MK. Kundu N, et al. Am J Physiol Cell Physiol. 2023 Feb 1;324(2):C320-C326. doi: 10.1152/ajpcell.00202.2022. Epub 2022 Dec 26. Am J Physiol Cell Physiol. 2023. PMID: 36571446 Free PMC article. Review.
LAM is characterized by dysregulation of many cell signaling pathways, distinct populations of LAM cells, and a rich microenvironment, in which the immune system appears to play an important role. This review delineates the heterogeneity of LAM and focuses on …
LAM is characterized by dysregulation of many cell signaling pathways, distinct populations of LAM cells, and a rich microenvi …
Targeting SPHK1/S1PR3-regulated S-1-P metabolic disorder triggers autophagic cell death in pulmonary lymphangiomyomatosis (LAM).
Li F, Zhang Y, Lin Z, Yan L, Liu Q, Li Y, Pei X, Feng Y, Han X, Yang J, Zheng F, Li T, Zhang Y, Fu Z, Shao D, Yu J, Li C. Li F, et al. Cell Death Dis. 2022 Dec 21;13(12):1065. doi: 10.1038/s41419-022-05511-3. Cell Death Dis. 2022. PMID: 36543771 Free PMC article.
Clinically, rapamycin shows limited cytocidal effects, and LAM recurs after drug withdrawal. In this study, we demonstrated that TSC2 negatively regulated the sphingolipid metabolism pathway and the expressions of sphingosine kinase 1 (SPHK1) and sphingosine-1-phosphate re …
Clinically, rapamycin shows limited cytocidal effects, and LAM recurs after drug withdrawal. In this study, we demonstrated that TSC2 …
Emerging biomarkers of lymphangioleiomyomatosis.
Nijmeh J, El-Chemaly S, Henske EP. Nijmeh J, et al. Expert Rev Respir Med. 2018 Feb;12(2):95-102. doi: 10.1080/17476348.2018.1409622. Epub 2017 Dec 1. Expert Rev Respir Med. 2018. PMID: 29171770 Review.
Lymphangioleiomyomatosis (LAM) is a destructive lung disease affecting primarily women. LAM is caused by inactivating mutations in the tuberous sclerosis complex (TSC) genes, resulting in hyperactivation of mechanistic/mammalian target of rapamycin complex 1 (mTORC1 …
Lymphangioleiomyomatosis (LAM) is a destructive lung disease affecting primarily women. LAM is caused by inactivating mutation …
Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.
Prizant H, Hammes SR. Prizant H, et al. Endocrinology. 2016 Sep;157(9):3374-83. doi: 10.1210/en.2016-1395. Epub 2016 Jul 13. Endocrinology. 2016. PMID: 27409646 Free PMC article. Review.
LAM cells metastasize to the lungs, predominantly through the lymphatics; however, the source of the LAM cell is still unknown. ...One of the biggest problems in treating LAM is that both the origin of the LAM cells and the mechanism of the sexual dimo …
LAM cells metastasize to the lungs, predominantly through the lymphatics; however, the source of the LAM cell is still unknown …
Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis.
Babaei-Jadidi R, Dongre A, Miller S, Castellanos Uribe M, Stewart ID, Thompson ZM, Nateri AS, Bradding P, May ST, Clements D, Johnson SR. Babaei-Jadidi R, et al. Am J Respir Crit Care Med. 2021 Aug 15;204(4):431-444. doi: 10.1164/rccm.202007-2854OC. Am J Respir Crit Care Med. 2021. PMID: 33882264
LAM lungs had increased tryptase-positive mast cells expressing CXCRs (CXC chemokine receptors) (P < 0.05). ...LAM spheroids caused mast-cell tryptase release, which induced fibroblast proliferation and increased LAM-spheroid size (1.36 0.24-fold; …
LAM lungs had increased tryptase-positive mast cells expressing CXCRs (CXC chemokine receptors) (P < 0.05). ...LAM s …
Glutaredoxin-1 promotes lymphangioleiomyomatosis progression through inhibiting Bim-mediated apoptosis via COX2/PGE2/ERK pathway.
Feng Y, Li T, Li Y, Lin Z, Han X, Pei X, Zhang Y, Li F, Yang J, Shao D, Li C. Feng Y, et al. Clin Transl Med. 2023 Jul;13(7):e1333. doi: 10.1002/ctm2.1333. Clin Transl Med. 2023. PMID: 37478294 Free PMC article.
Redox signalling through protein GSH adducts in LAM remains largely elusive. Here, we demonstrate the underlying mechanism of Glrx in the pathogenesis of LAM. ...CONCLUSIONS: Collectively, we provide a novel redox-dependent mechanism in the pathogenesis of LAM …
Redox signalling through protein GSH adducts in LAM remains largely elusive. Here, we demonstrate the underlying mechanism of Glrx in …
Meningiomas in lymphangioleiomyomatosis.
Moss J, DeCastro R, Patronas NJ, Taveira-DaSilva A. Moss J, et al. JAMA. 2001 Oct 17;286(15):1879-81. doi: 10.1001/jama.286.15.1879. JAMA. 2001. PMID: 11597290
Since 30% to 40% of patients with tuberous sclerosis complex (TSC) have LAM, we routinely screen patients with LAM for brain lesions found in TSC. ...Multiple meningiomas were observed in 2 patients. CONCLUSIONS: Women with LAM appear to have a high prevalenc …
Since 30% to 40% of patients with tuberous sclerosis complex (TSC) have LAM, we routinely screen patients with LAM for brain l …
Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).
Hammes SR, Krymskaya VP. Hammes SR, et al. Horm Cancer. 2013 Apr;4(2):70-7. doi: 10.1007/s12672-012-0128-4. Epub 2012 Nov 27. Horm Cancer. 2013. PMID: 23184699 Free PMC article. Review.
The only proven treatment for LAM is lung transplantation, and even then LAM cells will often return to the transplanted lung. ...This minireview summarizes recent progress in understanding LAM pathophysiology, including the latest preclinical and clinical st …
The only proven treatment for LAM is lung transplantation, and even then LAM cells will often return to the transplanted lung. …
8,859 results